Clinical Outcomes of Reduced‐Dose Cabozantinib as Third‐ or Later‐Line Therapy After Immune Checkpoint Inhibitors in Advanced Hepatocellular Carcinoma: A Real‐World Study
In real-world practice, cabozantinib is often initiated at reduced doses, yet DC can be achieved even at ∼20 mg/day. For patients with preserved liver function, long-term stable disease is attainable, and individualized dose-reduction strategies represent an effective and feasible approach in later-line HCC treatment after ICIs.
Authors
- S. Morisaki (ORCID: https://orcid.org/0000-0002-8445-6747)
- Yoshihiko Tachi (ORCID: https://orcid.org/0000-0001-9799-2445)
- Kohei Funasaka (ORCID: https://orcid.org/0000-0002-3869-1420)
- Eizaburo Ohno (ORCID: https://orcid.org/0000-0002-7730-4630)
- Teiji Kuzuya (ORCID: https://orcid.org/0000-0002-2229-990X)
- Ryoji Miyahara (ORCID: https://orcid.org/0000-0001-7172-4602)
- Kazunori Nakaoka (ORCID: https://orcid.org/0000-0002-7407-1763)
- Yoshiki Hirooka (ORCID: https://orcid.org/0000-0001-9639-7425)
- Takuji Nakano (ORCID: https://orcid.org/0000-0001-9914-3033)
- Hisanori Muto (ORCID: https://orcid.org/0000-0003-2121-2494)
- Mitsuo Nagasaka (ORCID: https://orcid.org/0000-0003-2099-6143)
- Gakushi Komura
- Hiroyuki Tanaka (ORCID: https://orcid.org/0000-0002-5087-5054)
- Mizuki Ariga
Institutions
- Fujita Health University (JP)
- Fujita Health University Hospital (JP)
- Fujita Health University Bantane Hospital
Publication Details
- Journal
- Hepatology Research
- Published
- 2025-11-27
- DOI
- https://doi.org/10.1111/hepr.70078
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00